Key Takeaways
Chinese biotech giant BeiGene Ltd. posted a 1.601 billion yuan first-quarter net profit, swinging from a loss a year earlier on strong sales of its flagship cancer treatments, and raised its full-year revenue guidance.
The company's product revenue for the first quarter of 2026 climbed to 10.321 billion yuan from 7.985 billion yuan in the same period last year, according to a company announcement.
The turnaround from a 94.5 million yuan loss in Q1 2025 was fueled by rising sales of its BTK inhibitor Brukinsa® (zanubrutinib) and the anti-PD-1 antibody Baize'an® (tislelizumab), alongside revenue from its portfolio of Amgen-licensed products. The growth demonstrates successful commercial execution for its core oncology portfolio.
Following the strong quarter, BeiGene adjusted its full-year 2026 operating revenue forecast to a range of 43.6 billion to 45.2 billion yuan. The robust performance and upgraded guidance signal sustained demand for its core oncology drugs, a key factor for investors tracking China's competitive biotech landscape.
The results underscore BeiGene's successful commercial execution and its transition to profitability. The performance of Brukinsa, in particular, remains a critical growth driver as it expands its market share globally, competing with other major BTK inhibitors. Investors will be watching to see if the company can maintain this momentum and achieve its new annual revenue targets amid a complex and evolving pharmaceutical market in China and abroad. The company's second-quarter results, expected in August 2026, will be the next major catalyst.
This article is for informational purposes only and does not constitute investment advice.
